MX2019015733A - Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. - Google Patents

Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.

Info

Publication number
MX2019015733A
MX2019015733A MX2019015733A MX2019015733A MX2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A MX 2019015733 A MX2019015733 A MX 2019015733A
Authority
MX
Mexico
Prior art keywords
saliva
melatonin
renders
soluble
acidifying agent
Prior art date
Application number
MX2019015733A
Other languages
English (en)
Spanish (es)
Inventor
M Shah Syed
Hassan Daniel
Hassan Fred
Corsino Patrick
Original Assignee
Physicians Seal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal Llc filed Critical Physicians Seal Llc
Publication of MX2019015733A publication Critical patent/MX2019015733A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019015733A 2017-06-20 2018-06-15 Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva. MX2019015733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (1)

Publication Number Publication Date
MX2019015733A true MX2019015733A (es) 2020-02-20

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015733A MX2019015733A (es) 2017-06-20 2018-06-15 Formulacion de melatonina oralmente disoluble con agente acidificante que produce melatonina soluble en saliva.

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200018652A (cg-RX-API-DMAC7.html)
CN (1) CN110913853A (cg-RX-API-DMAC7.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC7.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC7.html)
CA (1) CA3067822C (cg-RX-API-DMAC7.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019015733A (cg-RX-API-DMAC7.html)
RU (1) RU2020101742A (cg-RX-API-DMAC7.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC7.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2880618T3 (es) 2015-03-02 2021-11-25 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Also Published As

Publication number Publication date
WO2018236678A1 (en) 2018-12-27
US20200268886A1 (en) 2020-08-27
KR20200018652A (ko) 2020-02-19
US11224658B2 (en) 2022-01-18
RU2020101742A (ru) 2021-07-20
AU2018289284A1 (en) 2020-01-16
US20180360967A1 (en) 2018-12-20
SG11201912172YA (en) 2020-01-30
US10960075B2 (en) 2021-03-30
US11224657B2 (en) 2022-01-18
CN110913853A (zh) 2020-03-24
US20200069803A1 (en) 2020-03-05
US20200268887A1 (en) 2020-08-27
BR122021012549B1 (pt) 2022-02-22
ES2979335T3 (es) 2024-09-25
BR122021012549B8 (pt) 2022-10-25
JP7297685B2 (ja) 2023-06-26
CA3067822A1 (en) 2018-12-27
BR112019027286A2 (pt) 2020-07-21
EP3641759B1 (en) 2024-04-03
BR112019027286B1 (pt) 2022-02-22
US10500280B2 (en) 2019-12-10
EP3641759A4 (en) 2021-03-24
JP2020524162A (ja) 2020-08-13
CA3067822C (en) 2022-08-30
EP3641759A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
JOP20230278A1 (ar) تركيبة صيدلانية للوقاية من التليف أو علاجه
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2016014771A (es) Forma de dosificacion oralmente desintegrante para administracion de avanafil, y metodos de fabricacion y uso asociados.
JP2015038135A5 (cg-RX-API-DMAC7.html)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
BR112017026997A2 (pt) comprimido de rápida desintegração para ingestão oral contendo bactéria e método para produção
PH12015502274B1 (en) Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx
EP4442315A3 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
PH12016500119A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
AU2017260019A1 (en) Valerian composition and related methods
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
PL422140A1 (pl) Zastosowanie totarolu i kompozycja farmaceutyczna zawierająca totarol

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SOCIETE DES PRODUITS NESTLE S. A.